Published in J Clin Invest on August 01, 2006
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14
T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunol Cell Biol (2016) 1.08
CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood (2009) 1.04
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant (2011) 1.02
A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice. Clin Immunol (2014) 1.01
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes (2008) 0.94
Ligation of cytotoxic T lymphocyte antigen-4 to T cell receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells. J Biol Chem (2012) 0.89
Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J Immunol (2010) 0.88
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol (2011) 0.85
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity (2016) 0.84
Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res (2013) 0.84
Costimulation couture: a designer approach to regulating autoimmunity. J Clin Invest (2006) 0.82
Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci (2014) 0.80
Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. PLoS One (2011) 0.79
Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol (2012) 0.78
A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes. PLoS One (2013) 0.75
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
The B7 family revisited. Annu Rev Immunol (2005) 13.51
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
Following a diabetogenic T cell from genesis through pathogenesis. Cell (1993) 6.46
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med (2003) 4.68
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol (2005) 4.11
Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 4.05
Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A (2000) 3.89
Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 3.85
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (2002) 3.41
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
CTLA-4 regulates induction of anergy in vivo. Immunity (2001) 2.39
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell (1990) 2.20
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10
B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol (1998) 1.81
Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes (2004) 1.76
B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes (1997) 1.75
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 1.67
Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes (2004) 1.39
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24
Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 1.20
Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity (2002) 1.19
Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int Immunol (2003) 0.97
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol (2000) 0.96
Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J Neuroimmunol (1997) 0.92
Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo. Clin Immunol (2001) 0.88
Development and applications of surface-linked single chain antibodies against T-cell antigens. J Immunol Methods (2001) 0.83
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol (2002) 0.82
CTLA-4: acting at the synapse. Mol Interv (2002) 0.79
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (2011) 6.83
Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A (2010) 6.78
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature (2007) 5.82
Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol (2009) 5.59
Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003) 5.23
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity (2004) 4.81
Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature (2011) 4.71
Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med (2003) 4.68
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity (2008) 4.21
Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med (2006) 4.11
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med (2002) 3.80
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Type 2 innate lymphoid cells control eosinophil homeostasis. Nature (2013) 3.20
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol (2009) 3.17
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
A two-step process for cytokine production revealed by IL-4 dual-reporter mice. Immunity (2005) 3.02
Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell (2013) 3.00
Response to self antigen imprints regulatory memory in tissues. Nature (2011) 2.96
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
T-cell costimulation--biology, therapeutic potential, and challenges. N Engl J Med (2006) 2.81
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med (2013) 2.79
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol (2011) 2.67
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Activation of the integrated stress response during T helper cell differentiation. Nat Immunol (2006) 2.62
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Helper T cells regulate type-2 innate immunity in vivo. Nature (2002) 2.47
Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol (2013) 2.47
Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med (2006) 2.46
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2010) 2.37
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol (2009) 2.29
Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A (2003) 2.28
MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates. Kidney Int (2005) 2.25
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Loss of the LAT adaptor converts antigen-responsive T cells into pathogenic effectors that function independently of the T cell receptor. Immunity (2009) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol (2010) 2.09
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J Leukoc Biol (2007) 1.99
Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med (2007) 1.99
Regulation of hierarchical clustering and activation of innate immune cells by dendritic cells. Immunity (2008) 1.97
Memory regulatory T cells reside in human skin. J Clin Invest (2014) 1.95
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
Regulatory T cells in the periphery. Immunol Rev (2006) 1.94
Homeostasis and effector function of lymphopenia-induced "memory-like" T cells in constitutively T cell-depleted mice. J Immunol (2008) 1.91
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
The initial phase of an immune response functions to activate regulatory T cells. J Immunol (2009) 1.88
Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J Immunol (2006) 1.86
The renal mononuclear phagocytic system. J Am Soc Nephrol (2011) 1.84
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Interleukin-2 in the development and control of inflammatory disease. Immunol Rev (2008) 1.83
Genetic analysis of basophil function in vivo. Nat Immunol (2011) 1.82
Paths to understanding the genetic basis of autoimmune disease. Nature (2005) 1.79
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol (2010) 1.79
Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 1.76
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75